ArticleHeliyon2024
The gut-brain-axis: A positive relationship between gut microbial dysbiosis and glioblastoma brain tumour.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- The Microbiome in Glioblastoma: Mechanisms, Tumor-Immune Interactions, and Translational Perspectives.MicrobiologyOpen · 2026Review
- Gut microbiota composition and tumor immune features in meningioma patients.Microbiology spectrum · 2026Article
- Gut Dysbiosis Serine-Glycine Metabolism and Glioblastoma: Exploring Therapeutic Opportunities.Cancers · 2026Review
- Gut microbiota and glioblastoma: composition, mechanisms, and therapeutic interventions.Infectious agents and cancer · 2026Review
- 3-hydroxy-3-methylbutyrate (3H3MB) suppresses glioma growth and extends survival in mice.Frontiers in molecular neuroscience · 2026Article
- Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances.Military Medical Research · 2026Review
- Bidirectional Causal Effect Between Gut Microbiota and Glioma Risk: A Systematic Review-Based Mendelian Randomization and Immune-Mediated Effect Analysis.Cancer innovation · 2025Article
- Specific Intratumoral Microbiome Signatures in Human Glioblastoma and Meningioma: Evidence for a Gut-Brain Microbial Axis.International journal of molecular sciences · 2025Article
- Proteomics Approaches for Discovering Novel Protein Biomarkers in Inflammatory Bowel Disease-Related Cancer.Biomolecules · 2025Review
- Deciphering the Potential Causal and Prognostic Relationships Between Gut Microbiota and Brain Tumors: Insights from Genetics Analysis and Machine Learning.Exploration (Beijing, China) · 2025Article
- Intestinal Bacteroides drives glioma progression by regulating CD8+ T cell tumor infiltration.Neuro-oncology · 2025Article
- Metagenomics and transcriptomics analysis of aspartame's impact on gut microbiota and glioblastoma progression in a mouse model.Scientific reports · 2025Article
- Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology.International journal of molecular sciences · 2025Review
- Gut microbiota and their influence in brain cancer milieu.Journal of neuroinflammation · 2025Review
- The Role of Gut Microbiome on Glioblastoma Oncogenesis and Malignant Evolution.International journal of molecular sciences · 2025Review
- The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies.Cancers · 2025Review
- Modulation of the Neuro-Cancer Connection by Metabolites of Gut Microbiota.Biomolecules · 2025Review
- Brain Tumors and Beyond: Multi-Compartment Microbiome and Mycobiome Analysis.International journal of molecular sciences · 2025Article
- Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments.Frontiers in immunology · 2025Review
- Gut microbiota's role in glioblastoma risk, with a focus on the mediating role of metabolites.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glioblastoma brain tumour (GBM) stands out as the most aggressive and resistant-to-treatment malignancy. Nevertheless, the gut-brain connection plays a pivotal role in influencing the growth and activation of the central nervous system. In this particular investigation, we aimed to assess and characterize the gut microbial ecosystem in GBM patients, both quantitatively and qualitatively. We collected faecal samples from 15 healthy volunteers and 25 GBM patients. To delve into the microbial content, we employed PCR-DGGE, targeting the V3 region of the 16S rRNA gene, and conducted qPCR to measure the levels of crucial intestinal bacteria. For a more in-depth analysis, high-throughput sequencing was performed on a selection of 20 random faecal samples (10 from healthy individuals and 10 from GBM patients), targeting the V3+V4 region of the 16S rRNA gene. Our findings from examining the richness and diversity of the gut microbiota unveiled that GBM patients exhibited significantly higher microbial diversity compared to healthy individuals. At the phylum level, Proteobacteria saw a significant increase, while
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.